JP6306596B2 - セリンプロテアーゼ分子および療法 - Google Patents

セリンプロテアーゼ分子および療法 Download PDF

Info

Publication number
JP6306596B2
JP6306596B2 JP2015535813A JP2015535813A JP6306596B2 JP 6306596 B2 JP6306596 B2 JP 6306596B2 JP 2015535813 A JP2015535813 A JP 2015535813A JP 2015535813 A JP2015535813 A JP 2015535813A JP 6306596 B2 JP6306596 B2 JP 6306596B2
Authority
JP
Japan
Prior art keywords
grb
amino acid
antibody
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015535813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015532102A5 (cg-RX-API-DMAC7.html
JP2015532102A (ja
Inventor
マイケル ジー． ローゼンブルム，
マイケル ジー． ローゼンブルム，
カーリッド アマナリ モハメダリ，
カーリッド アマナリ モハメダリ，
ローレンス エイチ． チェン，
ローレンス エイチ． チェン，
Original Assignee
リサーチ ディベロップメント ファウンデーション
リサーチ ディベロップメント ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49447827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6306596(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by リサーチ ディベロップメント ファウンデーション, リサーチ ディベロップメント ファウンデーション filed Critical リサーチ ディベロップメント ファウンデーション
Publication of JP2015532102A publication Critical patent/JP2015532102A/ja
Publication of JP2015532102A5 publication Critical patent/JP2015532102A5/ja
Application granted granted Critical
Publication of JP6306596B2 publication Critical patent/JP6306596B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
JP2015535813A 2012-10-04 2013-10-04 セリンプロテアーゼ分子および療法 Active JP6306596B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261709763P 2012-10-04 2012-10-04
US61/709,763 2012-10-04
US201361762216P 2013-02-07 2013-02-07
US201361762173P 2013-02-07 2013-02-07
US61/762,216 2013-02-07
US61/762,173 2013-02-07
PCT/US2013/063402 WO2014055836A2 (en) 2012-10-04 2013-10-04 Serine protease molecules and therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017102733A Division JP6722134B2 (ja) 2012-10-04 2017-05-24 セリンプロテアーゼ分子および療法

Publications (3)

Publication Number Publication Date
JP2015532102A JP2015532102A (ja) 2015-11-09
JP2015532102A5 JP2015532102A5 (cg-RX-API-DMAC7.html) 2016-11-24
JP6306596B2 true JP6306596B2 (ja) 2018-04-04

Family

ID=49447827

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015535813A Active JP6306596B2 (ja) 2012-10-04 2013-10-04 セリンプロテアーゼ分子および療法
JP2017102733A Active JP6722134B2 (ja) 2012-10-04 2017-05-24 セリンプロテアーゼ分子および療法
JP2017165526A Withdrawn JP2017205128A (ja) 2012-10-04 2017-08-30 セリンプロテアーゼ分子および療法
JP2019177328A Withdrawn JP2019214628A (ja) 2012-10-04 2019-09-27 セリンプロテアーゼ分子および療法
JP2021215386A Active JP7403521B2 (ja) 2012-10-04 2021-12-29 セリンプロテアーゼ分子および療法
JP2023013891A Pending JP2023041829A (ja) 2012-10-04 2023-02-01 セリンプロテアーゼ分子および療法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017102733A Active JP6722134B2 (ja) 2012-10-04 2017-05-24 セリンプロテアーゼ分子および療法
JP2017165526A Withdrawn JP2017205128A (ja) 2012-10-04 2017-08-30 セリンプロテアーゼ分子および療法
JP2019177328A Withdrawn JP2019214628A (ja) 2012-10-04 2019-09-27 セリンプロテアーゼ分子および療法
JP2021215386A Active JP7403521B2 (ja) 2012-10-04 2021-12-29 セリンプロテアーゼ分子および療法
JP2023013891A Pending JP2023041829A (ja) 2012-10-04 2023-02-01 セリンプロテアーゼ分子および療法

Country Status (7)

Country Link
US (8) US9096840B2 (cg-RX-API-DMAC7.html)
EP (3) EP4029937A1 (cg-RX-API-DMAC7.html)
JP (6) JP6306596B2 (cg-RX-API-DMAC7.html)
AU (2) AU2013326933B2 (cg-RX-API-DMAC7.html)
CA (1) CA2885376C (cg-RX-API-DMAC7.html)
DK (1) DK3456734T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014055836A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4029937A1 (en) 2012-10-04 2022-07-20 Research Development Foundation Serine protease molecules and therapies
KR102488961B1 (ko) * 2014-05-19 2023-01-16 삼성전자주식회사 그랜자임 b를 포함하는 융합 단백질 및 이의 용도
GB2530479A (en) * 2014-08-06 2016-03-30 Hilmar Meek Warenius Peptides useful for treating cancer
WO2016100233A1 (en) * 2014-12-15 2016-06-23 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
DK3240805T3 (da) 2014-12-15 2025-02-10 Univ California Bispecifik or-gate kimærisk antigenreceptor, som reagerer på cd19 og cd20
RU2020127887A (ru) 2015-03-11 2020-10-02 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Полипептиды транспозазы и их применение
CA3004306A1 (en) 2015-11-04 2017-05-11 Stephen J. Forman Chimeric antigen receptors targeting her2
GB201602409D0 (en) * 2016-02-10 2016-03-23 Warenius Hilmar M Compositions and uses thereof
DK3417058T3 (da) 2016-02-16 2021-11-15 Res Found Dev Sortase-modificerede molekyler og anvendelser deraf
JP7068702B2 (ja) * 2016-06-02 2022-05-17 国立研究開発法人理化学研究所 アジュバント組成物とその利用
JP7239987B2 (ja) * 2016-06-06 2023-03-15 アスクリピウム タイワン シーオー．， エルティーディー． 薬物送達のための抗体融合タンパク質
CA3039136A1 (en) 2016-09-02 2018-03-08 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
CN106554422A (zh) * 2016-10-26 2017-04-05 天津科技大学 高透皮吸收皮下靶向释放型因子及构建方法和应用
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2019075270A1 (en) * 2017-10-12 2019-04-18 Amesino Llc VEGFR ANTIBODY LIGHT CHAIN FUSION PROTEIN
WO2019126960A1 (zh) * 2017-12-25 2019-07-04 清华大学 一种具有蛋白酶活性的多肽及其应用
CN112041333B (zh) * 2018-04-26 2024-06-28 古德T细胞有限公司 新型融合蛋白和用于预防或治疗癌症的包含该融合蛋白的药物组合物
KR102875649B1 (ko) * 2018-11-26 2025-10-23 삼성디스플레이 주식회사 유기금속 화합물 및 이를 포함한 유기 발광 소자
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
US20230203108A1 (en) * 2020-05-28 2023-06-29 Chugai Seiyaku Kabushiki Kaisha Improved granzyme b variant
AU2022361048A1 (en) * 2021-10-07 2024-05-02 Omeros Corporation Targeted catalytic complement-activating molecules and methods of use thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5141648A (en) 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
CA2115049C (en) 1991-09-06 2003-10-21 Michael G. Rosenblum Dna sequences encoding gelonin polypeptide
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
IL116559A (en) 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US7183388B2 (en) 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
WO2003007889A2 (en) 2001-07-17 2003-01-30 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2003243436A1 (en) 2002-06-06 2003-12-22 Shohei Koide Reconstituted polypeptides
US20050074865A1 (en) * 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
AU2003282724B2 (en) * 2002-10-02 2010-03-04 Catalyst Biosciences, Inc. Methods of generating and screening for proteases with altered specificity
EP2308901B1 (en) * 2003-04-23 2017-11-08 F. Hoffmann-La Roche AG Cleavage of fusion proteins using Granzyme B protease
JP2006527192A (ja) * 2003-06-05 2006-11-30 リサーチ ディベロップメント ファウンデーション 血管内皮増殖因子融合構築物およびその使用方法
US7601341B2 (en) 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
US20060234299A1 (en) 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
AU2006203850A1 (en) 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
DE102005061886A1 (de) 2005-12-23 2007-07-05 Robert Bosch Gmbh Hochdruckpumpe, insbesondere für eine Kraftstoffeinspritzeinrichtung einer Brennkraftmaschine
CA2645277A1 (en) 2006-03-09 2007-09-13 Wadih Arap Compositions and methods based on peptide binding profiling
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
ATE555200T1 (de) 2008-02-05 2012-05-15 Medical Res Council Verfahren und zusammensetzungen
CN101684159B (zh) * 2008-09-27 2013-04-24 中国医学科学院基础医学研究所 人颗粒酶b蛋白衍生物及其在靶向治疗腺癌中的用途
WO2010045469A2 (en) 2008-10-15 2010-04-22 The Board Of Regents Of The University Of Texas System Muc18 targeting peptides
ES2693232T3 (es) * 2010-11-30 2018-12-10 Chugai Seiyaku Kabushiki Kaisha Agente terapéutico que induce citotoxicidad
US9528101B2 (en) * 2011-09-23 2016-12-27 PHARMED ARTIS GmbH Granzyme B protease variants
EP4029937A1 (en) 2012-10-04 2022-07-20 Research Development Foundation Serine protease molecules and therapies

Also Published As

Publication number Publication date
CA2885376C (en) 2025-05-13
US20200308565A1 (en) 2020-10-01
US20150010556A1 (en) 2015-01-08
EP3456734B1 (en) 2022-01-05
JP7403521B2 (ja) 2023-12-22
US20200010821A1 (en) 2020-01-09
AU2013326933B2 (en) 2017-10-05
JP2023041829A (ja) 2023-03-24
WO2014055836A3 (en) 2014-05-30
JP6722134B2 (ja) 2020-07-15
JP2017140051A (ja) 2017-08-17
US20190256837A1 (en) 2019-08-22
EP3456734A1 (en) 2019-03-20
US20230203467A1 (en) 2023-06-29
JP2022033246A (ja) 2022-02-28
AU2017228534A1 (en) 2017-10-05
CA2885376A1 (en) 2014-04-10
US11535838B2 (en) 2022-12-27
US10323239B2 (en) 2019-06-18
US20140140976A1 (en) 2014-05-22
WO2014055836A2 (en) 2014-04-10
JP2015532102A (ja) 2015-11-09
US9096840B2 (en) 2015-08-04
EP4029937A1 (en) 2022-07-20
US10920211B2 (en) 2021-02-16
US9499807B2 (en) 2016-11-22
US20140314760A1 (en) 2014-10-23
JP2019214628A (ja) 2019-12-19
EP2904004B1 (en) 2018-11-21
DK3456734T3 (da) 2022-04-19
AU2017228534B2 (en) 2019-07-11
JP2017205128A (ja) 2017-11-24
AU2013326933A1 (en) 2015-04-02
US10738295B2 (en) 2020-08-11
EP2904004A2 (en) 2015-08-12
US9951325B2 (en) 2018-04-24
US20180201918A1 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
JP7403521B2 (ja) セリンプロテアーゼ分子および療法
US11913043B2 (en) Cell-targeted cytotoxic constructs
US11912747B2 (en) Chimeric proteins for targeting dsRNA
US20190255146A1 (en) Polypeptides for improved response to anti-cancer therapy
CN111263640A (zh) 组织因子靶向car-nk和car-t细胞疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161004

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20161004

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20161028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171220

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20171228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180308

R150 Certificate of patent or registration of utility model

Ref document number: 6306596

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250